Network


Latest external collaboration on country level. Dive into details by clicking on the dots.

Hotspot


Dive into the research topics where Marianna Criscuolo is active.

Publication


Featured researches published by Marianna Criscuolo.


Journal of Clinical Oncology | 2013

Revised International Prognostic Scoring System (IPSS) Predicts Survival and Leukemic Evolution of Myelodysplastic Syndromes Significantly Better Than IPSS and WHO Prognostic Scoring System: Validation by the Gruppo Romano Mielodisplasie Italian Regional Database

Maria Teresa Voso; Susanna Fenu; Roberto Latagliata; Francesco Buccisano; Alfonso Piciocchi; Maria Antonietta Aloe-Spiriti; Massimo Breccia; Marianna Criscuolo; Alessandro Andriani; Stefano Mancini; Pasquale Niscola; Virginia Naso; Carolina Nobile; Anna Lina Piccioni; Mariella D'Andrea; Ada D'Addosio; Giuseppe Leone; Adriano Venditti

PURPOSE The definition of disease-specific prognostic scores plays a fundamental role in the treatment decision-making process in myelodysplastic syndrome (MDS), a group of myeloid disorders characterized by a heterogeneous clinical behavior. PATIENTS AND METHODS We applied the recently published Revised International Prognostic Scoring System (IPSS-R) to 380 patients with MDS, registered in an Italian regional database, recruiting patients from the city of Rome (Gruppo Romano Mielodisplasie). Patients were selected based on the availability of IPSS-R prognostic factors, including complete peripheral-blood and bone marrow counts, informative cytogenetics, and follow-up data. RESULTS We validated the IPSS-R score as a significant predictor of overall survival (OS) and leukemia-free survival (LFS) in MDS (P < .001 for both). When comparing the prognostic value of the International Prognostic Scoring System (IPSS), WHO Prognostic Scoring System (WPSS), and IPSS-R, using the Cox regression model and the likelihood ratio test, a significantly higher predictive power for LFS and OS became evident for the IPSS-R, compared with the IPSS and WPSS (P < .001 for both). The multivariate analysis, including IPSS, WPSS, age, lactate dehydrogenase, ferritin concentration, Eastern Cooperative Oncology Group performance status, transfusion dependency, and type of therapy, confirmed the significant prognostic value of IPSS-R subgroups for LFS and OS. Treatment with lenalidomide and erythropoiesis-stimulating agents was shown to be an independent predictor of survival in the multivariate analysis. CONCLUSION Our data confirm that the IPSS-R is an excellent prognostic tool in MDS in the era of disease-modifying treatments. The early recognition of patients at high risk of progression to aggressive disease may optimize treatment timing in MDS.


Annals of Oncology | 2009

Cell-free circulating DNA in Hodgkin's and non-Hodgkin's lymphomas

Stefan Hohaus; Manuela Giachelia; Giuseppina Massini; Giovanna Mansueto; Barbara Vannata; Valentina Bozzoli; Marianna Criscuolo; Francesco D'Alo'; Maurizio Martini; Luigi Maria Larocca; Maria Teresa Voso; Giuseppe Leone

BACKGROUND Levels of cell-free circulating DNA have been correlated to clinical characteristics and prognosis in patients with cancers of epithelial origin, while there are no data on patients with B-lymphoproliferative diseases. PATIENTS AND METHODS Cell-free DNA levels in the plasma samples of 142 patients with lymphomas [45 with Hodgkins lymphoma (HL), 63 with diffuse large B-cell non-Hodgkins lymphoma (DLBCL), 24 with follicular, and 10 with mantle cell non-Hodgkins lymphoma (NHL)] at diagnosis and of 41 healthy individuals were determined using a quantitative PCR for the beta-globin gene. RESULTS Levels of circulating DNA in patients with HL, DLBCL, and mantle cell NHL were significantly higher than in controls (P < 0.01 for all). Increased levels of plasma DNA were associated with advanced stage disease, presence of B-symptoms, elevated lactate dehydrogenase levels, and age >60 years (P = 0.009; <0.0001; <0.0001; 0.04, respectively). In HL, histological signs of necrosis and grade 2 type of nodular sclerosis were associated with increased plasma DNA. Elevated plasma DNA levels were associated with an inferior failure-free survival in patients with HL (P = 0.01) and DLBCL (P = 0.03). CONCLUSION Quantification of circulating DNA by real-time PCR at diagnosis can identify patients with elevated levels that are associated with disease characteristics indicating aggressive disease and poor prognosis.


Leukemia & Lymphoma | 2013

High rate of remissions in chronic myelomonocytic leukemia treated with 5-azacytidine: results of an Italian retrospective study

Luana Fianchi; Marianna Criscuolo; Massimo Breccia; Luca Maurillo; Flavia Salvi; Pellegrino Musto; Giovanna Mansueto; Gianluca Gaidano; C. Finelli; A Aloe-Spiriti; Santini; Michele Mario Greco; Stefan Hohaus; Giuseppe Leone; Maria Teresa Voso

1 Istituto di Ematologia, Universit à Cattolica del Sacro Cuore, Roma, Italy, 2 Dipartimento di Biotecnologie Cellulari ed Ematologia, Universit à La Sapienza, Roma, Italy, 3 Istituto di Ematologia, Fondazione Policlinico Tor Vergata, Roma, Italy, 4 Ematologia, A.O. SS Antonio e Biagio e Cesare Arrigo, Alessandria, Italy, 5 Dipartimento di Onco-Hematology, IRCCS, Centro di Riferimento Oncologico della Basilicata, Rionero in Vulture, Italy, 6 Divisione di Ematologia, Dipartimento di Medicina Traslazionale, Universit à del Piemonte Orientale Amedeo Avogadro, Novara, Italy, 7 S.Orsola-Malpighi University Hospital, Department of Hematology and Oncological Sciences “Ser à gnoli”, Bologna, Italy, 8 Dipartimento di Ematologia, Ospedale Sant ’ Andrea, Universit à La Sapienza, Roma, Italy and 9 Ematologia, AOU Careggi, Universit à di Firenze, Firenze, Italy


Chemico-Biological Interactions | 2010

Epigenetic changes in therapy-related MDS/AML

Maria Teresa Voso; Francesco D’Alò; Mariangela Greco; Emiliano Fabiani; Marianna Criscuolo; Giuseppe Migliara; Livio Pagano; Luana Fianchi; Francesco Guidi; Stefan Hohaus; Giuseppe Leone

Therapy-related Myelodysplastic Syndromes/Acute Myeloid Leukemias (t-MDS/AML) are one of the most compelling long term adverse events occurring in cancer survivors treated with chemo-radiotherapy regimes. Beside several well-described genetic lesions, a growing amount of data suggests that abnormalities in DNA methylation profile contribute to multistep secondary leukemogenesis. Two distinct alterations of normal DNA methylation patterns may occur in cancer: a global hypomethylation resulting in chromosomal instability and loss of genetic integrity, and promoter specific DNA hypermethylation which leads to silencing of tumor suppressor genes. Cytotoxic drugs and radiation have been shown to affect tissue DNA methylation profile. Radiation is able to induce a stable DNA hypomethylation in both target and bystander tissues. Gene promoter methylation is a common finding in t-MDS/AML and has been associated to a shorter latency period from the treatment of the primary tumor. Among the studied genes, p15 methylation correlated to monosomy/deletion of chromosome 7q, suggesting that it could be a relevant event in alkylating agent-induced leukemogenesis. We found frequent methylation of DAPK in the t-MDS/AML group, especially in patients with a previous lymphoproliferative disease. In patients studied for concurrent methylation of several promoters, t-MDS/AML were significantly more frequently hypermethylated in 2 or more promoter regions than de novo MDS or AML suggesting that promoter hypermethylation of genes involved in cell cycle control, apoptosis and DNA repair pathways is a frequent finding in t-MDS/AML and may contribute to secondary leukemogenesis. However, how the epigenetic machinery is disrupted after chemo/radiotherapy and during secondary carcinogenesis is still unknown, warranting further studies.


Journal of Hematology & Oncology | 2012

Outcome of therapy-related myeloid neoplasms treated with azacitidine

Luana Fianchi; Marianna Criscuolo; Monia Lunghi; Gianluca Gaidano; Massimo Breccia; Alessandro Levis; Carlo Finelli; Valeria Santini; Pellegrino Musto; Esther Oliva; Pietro Leoni; Antonietta Aloe Spiriti; Francesco D’Alò; Stefan Hohaus; Livio Pagano; Giuseppe Leone; Maria Teresa Voso

BackgroundTherapy-related myeloid neoplasms (t-MN), including myelodysplastic syndromes and acute myeloid leukemia (t-MDS and t-AML) are associated to clinical and biologic unfavorable prognostic features, including high levels of DNA methylation.MethodsWe retrospectively evaluated 50 t-MN patients (34 MDS and 16 AML) selected among all patients receiving azacitidine (AZA) at 10 Italian Hematology Centers. Patients had developed a t-MN at a median of 6.5 years (range 1.7- 29) after treatment of the primary tumor (hematological neoplasm, 27 patients; solid tumor, 23 patients).ResultsThe overall response rate was 42% (complete remission: 10 patients, partial remission: 2 and hematological improvement: 8 patients) and was obtained after a median of 3 cycles (range 1–6). Median overall survival (OS) was 21 months (range 1–53.6+) from AZA start. OS was significantly better in patients with less than 20% blasts, in normal karyotype t-AML and when AZA was used as front-line treatment. This was confirmed by the multivariate analysis.ConclusionsThis study reports efficacy of AZA in the largest series of therapy-related MN patients treated with 5-AZA. Our data show that blasts and karyotype maintain their important prognostic role in t-MN also in the azacitidine era.


Leukemia | 2011

Role of BCL2L10 methylation and TET2 mutations in higher risk myelodysplastic syndromes treated with 5-azacytidine

Maria Teresa Voso; Emiliano Fabiani; Alfonso Piciocchi; Caterina Matteucci; Lucia Brandimarte; Carlo Finelli; Enrico Maria Pogliani; Emanuele Angelucci; Giuseppe Fioritoni; Pellegrino Musto; Mariangela Greco; Marianna Criscuolo; Luana Fianchi; Marco Vignetti; Santini; Stefan Hohaus; Christina Mecucci; Giuseppe Leone

Role of BCL2L10 methylation and TET2 mutations in higher risk myelodysplastic syndromes treated with 5-Azacytidine


Leukemia & Lymphoma | 2010

Analysis of genome-wide methylation and gene expression induced by 5-aza-2'-deoxycytidine identifies BCL2L10 as a frequent methylation target in acute myeloid leukemia

Emiliano Fabiani; Giuseppe Leone; Manuela Giachelia; Francesco D'Alo'; Mariangela Greco; Marianna Criscuolo; Francesco Guidi; Sergio Rutella; Stefan Hohaus; Maria Teresa Voso

Epigenetic changes play a role in the pathogenesis of myeloid malignancies, and hypomethylating agents have shown efficacy in these diseases. We studied the apoptotic effect, genome-wide methylation, and gene expression profiles in HL60 cells following 5-aza-2′-deoxycytidine (decitabine; DAC) treatment, using microarray technologies. Decitabine treatment resulted in a decrease in global DNA methylation, corresponding to 4876 probeset IDs with significantly reduced methylation levels, while the expression of 2583 IDs was modified. The integrated analysis identified 160 genes demethylated and up-regulated by decitabine, mainly including development and differentiation pathway genes. Gene targets of Polycomb group protein regulation were overrepresented in this group. Apoptosis was induced by decitabine, and apoptosis-specific PCR arrays more precisely indicated decitabine-induced up-regulation of 13 apoptosis-related genes, in particular DAP-kinase 1 and BCL2L10. Correspondingly, in primary patient samples, BCL2L10 was hypermethylated in 45% of AML, 43% of therapy-related myeloid neoplasms, 12% of MDS, and in none of the controls. In conclusion, decitabine induces global demethylation and gene expression, in particular of Polycomb target genes involved in development and differentiation pathways. The apoptotic gene BCL2L10 is a frequent target for aberrant promoter methylation in patients with acute leukemia, de novo and therapy-related.


Leukemia Research | 2009

Clinical significance of interleukin-10 gene polymorphisms and plasma levels in Hodgkin lymphoma

Stefan Hohaus; Manuela Giachelia; Giuseppina Massini; Barbara Vannata; Marianna Criscuolo; Maurizio Martini; Francesco D'Alo'; Maria Teresa Voso; Luigi Maria Larocca; Giuseppe Leone

We studied plasma levels of IL-10 and five single nucleotide polymorphisms in the interleukin-10 (IL-10) gene promoter in patients with Hodgkin lymphoma (HL) to address potential genotype-phenotype correlations. Patients with elevated IL-10 levels were more likely to have advanced stage disease and inferior event-free survival. Homozygous carriers of the variant alleles at position -592 (AA) and -1082 (GG) of the IL-10 promoter had higher IL-10 plasma levels, independent of male gender and advanced stage of disease which also determined increased IL-10 production. This analysis indicates that the genetic background can modulate plasma levels of IL-10, and ultimately prognosis in HL.


Haematologica | 2014

Why methylation is not a marker predictive of response to hypomethylating agents.

Maria Teresa Voso; Santini; Emiliano Fabiani; Luana Fianchi; Marianna Criscuolo; Giulia Falconi; Francesco Guidi; Stefan Hohaus; Giuseppe Leone

The azanucleotides azacitidine and decitabine have been shown to induce hematologic response and prolong survival in higher-risk myelodysplastic syndromes. They are inhibitors of DNA methyltransferase-1 and induce DNA-hypomethylation. Induction of apoptosis is also clinically relevant, in particular during the first treatment cycles, when cytopenia is a frequent side-effect. Since the hypomethylating effect is reversible, and the malignant clone has been shown to persist in most responding patients, several cycles are necessary to achieve and maintain responses, while treatment interruption is associated with rapid relapse. Methylation studies have shown global and gene-specific hypermethylation in myelodysplastic syndromes, but there seems to be little relation between the degree of demethylation following hypomethylating treatment and hematologic response. The presence of concurrent genomic hypermethylation and hypomethylation may impair the predictive power of current detection techniques. This scenario has been complicated by the identification of epigenetic enzyme mutations, including TET2, IDH1/2, DNMT3A and EZH2, which are important for response to hypomethylating treatment. Changes in azanucleotide metabolism genes may also play a role. In the future, methylation analysis concentrating not only on promoters, but also on gene bodies and intergenic regions, may identify key genes in patients with the highest probability of response to azanucleotides and allow a patient-tailored approach.


Blood Cells Molecules and Diseases | 2010

Promoter methylation of DAPK1, E-cadherin and thrombospondin-1 in de novo and therapy-related myeloid neoplasms

Mariangela Greco; Francesco D'Alo'; Alessandra Scardocci; Marianna Criscuolo; Emiliano Fabiani; Francesco Guidi; Annalisa Di Ruscio; Giuseppe Migliara; Livio Pagano; Luana Fianchi; Patrizia Chiusolo; Stefan Hohaus; Giuseppe Leone; Maria Teresa Voso

DNA methylation is one of the major epigenetic changes in human cancers, leading to silencing of tumor suppressor genes, with a pathogenetic role in tumor development and progression in myelodysplastic syndromes (MDS) and acute myeloid leukemia (AML). Methylation of key promoter regions, induced by cytotoxic therapy together with complex genetic changes, is important in the biology of therapy-related myeloid neoplasms (t-MN). We were interested in the characterization of the methylation pattern of AML and MDS de novo and therapy-related. We studied 385 patients (179 females, 206 males), of a median age of 66 years (range 16-98 years). There were 105 MDS, 208 de novo AML and 72 t-MN (45 MDS and 27 AML). Using a methylation-specific PCR, we studied the promoter methylation status of E-cadherin (CDH1), TSP1 and DAP-Kinase 1. These genes have been shown to be involved in the malignant transformation, interfering with angiogenesis, interaction with micro-environment, apoptosis and xenobiotic detoxification. We found no associations between promoter hypermethylation and gender or age at the time of initial diagnosis. In patients with MDS, there were no associations between hypermethylation and clinical characteristics, including IPSS score, WHO classification and cytogenetics. DAPK1 was more frequently methylated in t-MDS/AML when compared to de novo MDS and AML (39% vs 15.3% and 24.4%, p=0.0001), while methylation of CDH1 was similar in t-MDS/AML and AML (51% and 53.4%), but less frequent in de novo MDS (29%) (p=0.003). In the t-MDS/AML group, we found that the methylation pattern appeared to be related to the primary tumor, with DAPK1 more frequently methylated in patients with a previous lymphoproliferative disease (75% vs 32%, p=0.006). On the other hand, methylation of CDH1 was associated to radiotherapy for the primary malignancy (84.5% vs 38%, p=0.003). TSP1 hypermethylation was rare and not characteristic of t-MDS/AML. In 177 patients studied for concurrent methylation of several promoters, t-MN and AML de novo were significantly more frequently hypermethylated in 2 or more promoter regions than de novo MDS (20% vs 12.4%, p<0.001). Chemotherapy and individual genetic predisposition have a role in t-MDS/AML development, the identification of specific epigenetic modifications may explain complexity and genomic instability of these diseases and give the basis for targeted-therapy. The significant association with previous malignancy subtypes may underlie a likely susceptibility to methylation of specific targets and a role for constitutional epimutations as predisposing factors for the development of therapy-related myeloid neoplasm.

Collaboration


Dive into the Marianna Criscuolo's collaboration.

Top Co-Authors

Avatar

Maria Teresa Voso

The Catholic University of America

View shared research outputs
Top Co-Authors

Avatar

Luana Fianchi

The Catholic University of America

View shared research outputs
Top Co-Authors

Avatar

Giuseppe Leone

The Catholic University of America

View shared research outputs
Top Co-Authors

Avatar

Livio Pagano

Catholic University of the Sacred Heart

View shared research outputs
Top Co-Authors

Avatar

Emiliano Fabiani

The Catholic University of America

View shared research outputs
Top Co-Authors

Avatar

Stefan Hohaus

Catholic University of the Sacred Heart

View shared research outputs
Top Co-Authors

Avatar

Massimo Breccia

Sapienza University of Rome

View shared research outputs
Top Co-Authors

Avatar

Giulia Falconi

Catholic University of the Sacred Heart

View shared research outputs
Top Co-Authors

Avatar

Francesco Buccisano

University of Rome Tor Vergata

View shared research outputs
Top Co-Authors

Avatar

Luca Maurillo

University of Rome Tor Vergata

View shared research outputs
Researchain Logo
Decentralizing Knowledge